Immunoglobulin G1 (IgG1) is a type of antibody that plays a crucial role in the immune response by recognizing and binding to specific antigens. The substance in question, "Immunoglobulin G1, anti-(human 5′-nucleotidase) (human monoclonal MEDI9447 heavy chain), disulfide with human monoclonal MEDI9447 λ-chain, dimer," is a dimeric form of a monoclonal antibody specifically targeting human 5′-nucleotidase, an enzyme involved in nucleotide metabolism. This antibody is composed of two heavy chains and two light chains, linked by disulfide bonds, which contribute to its structural stability and functionality. The dimeric nature enhances its avidity for the target antigen, potentially improving therapeutic efficacy. IgG1 antibodies are characterized by their ability to activate complement and mediate antibody-dependent cellular cytotoxicity (ADCC), making them valuable in therapeutic applications, including cancer treatment and autoimmune diseases. The CAS number 1803176-05-7 uniquely identifies this specific antibody, facilitating its recognition in scientific literature and regulatory contexts.

Immunoglobulin G1, anti-(human 5′-nucleotidase) (human monoclonal MEDI9447 heavy chain), disulfide with human monoclonal MEDI9447 λ-chain, dimer

1803176-05-7: Immunoglobulin G1 (IgG1) is a type of antibody that plays a crucial role in the immune response by recognizing and binding to specific antigens. The substance in question, "Immunoglobulin G1, anti-(human 5′-nucleotidase) (human monoclonal MEDI9447 heavy chain), disulfide with human monoclonal MEDI9447 λ-chain, dimer," is a dimeric form of a monoclonal antibody specifically targeting human 5′-nucleotidase, an enzyme involved in nucleotide metabolism. This antibody is composed of two heavy chains and two light chains, linked by disulfide bonds, which contribute to its structural stability and functionality. The dimeric nature enhances its avidity for the target antigen, potentially improving therapeutic efficacy. IgG1 antibodies are characterized by their ability to activate complement and mediate antibody-dependent cellular cytotoxicity (ADCC), making them valuable in therapeutic applications, including cancer treatment and autoimmune diseases. The CAS number 1803176-05-7 uniquely identifies this specific antibody, facilitating its recognition in scientific literature and regulatory contexts.

<p>Oleclumab (MEDI9447) is a human anti-CD73 monoclonal antibody with anticancer activity for the study of metastatic desmoplastic resistant prostate cancer.</p>

Oleclumab

<p>Anti-Human CD73 Monoclonal Antibody</p>

CAS 1803176-05-7

Immunoglobulin G1, anti-(human 5′-nucleotidase) (human monoclonal MEDI9447 heavy chain), disulfide with human monoclonal MEDI9447 λ-chain, dimer

Oleclumab

Ref: TM-T76695

Oleclumab

Ref: 3D-CLA1478